Precision Medicine

How is AI Transforming Breast Cancer Screening and Risk Reduction?
Tech & Innovation How is AI Transforming Breast Cancer Screening and Risk Reduction?

Artificial intelligence (AI) is dramatically revolutionizing the field of breast cancer screening and risk reduction by introducing advanced methods for analyzing mammographic images and identifying new risk predictors. With these innovations, the medical community is moving towards more

How Are Portable MRIs and AI Transforming Alzheimer's Diagnosis?
Tech & Innovation How Are Portable MRIs and AI Transforming Alzheimer's Diagnosis?

Alzheimer’s disease (AD) is a progressive neurodegenerative condition that significantly impacts memory, cognition, and behavior. Early detection is crucial for effective intervention, especially with the development of new anti-amyloid therapies. However, traditional diagnostic tools face

Can mTOR Inhibitors Treat Rare Genetic Immunodeficiency Disorders?
Research & Development Can mTOR Inhibitors Treat Rare Genetic Immunodeficiency Disorders?

Genetic mutations causing rare immunodeficiency disorders present significant challenges to medical science, but recent advancements offer hope to affected individuals. University of Surrey researchers have made promising strides in understanding and potentially treating these conditions,

Modified Chemotherapy Regimen Reduces Long-Term Side Effects in Hodgkin Lymphoma
Research & Development Modified Chemotherapy Regimen Reduces Long-Term Side Effects in Hodgkin Lymphoma

Hodgkin lymphoma, a rare but treatable blood cancer, primarily impacts younger individuals aged 20-40. Effective treatment is crucial, but so is the consideration of long-term health and quality of life for patients. Recent advancements in chemotherapy regimens have shown promise in reducing

Can Immunotherapy Before and After Surgery Improve NSCLC Outcomes?
Research & Development Can Immunotherapy Before and After Surgery Improve NSCLC Outcomes?

The PROSPECT-Lung trial has officially commenced, heralding a significant advance in the quest to enhance treatment strategies for patients with resectable non-small cell lung cancer (NSCLC). This trial marks the inaugural endeavor of the newly established National Cancer Institute (NCI) Clinical

High-Dose Chemotherapy and ASCT No Extra Benefit in MCL Remission
Research & Development High-Dose Chemotherapy and ASCT No Extra Benefit in MCL Remission

The findings from the late-breaking research presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition have brought new insights into the treatment of mantle cell lymphoma (MCL). The phase 3 study EA4151, conducted by the ECOG-ACRIN Cancer Research Group, investigated

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later